Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Integrate Compact disc Rates into Your Retirement Arranging19.10.2023 - 24 Excellent Remote Headphones of 202405.06.2024
- 3Real time features for Films and Programs06.06.2024
- 4Manual for Wonderful Getaway destination05.06.2024
- 5She was the supermodel dubbed 'The Face' in the '80s. Joining OnlyFans in her 60s taught her a lot.11.12.2025
- ‘Grit’ and relentless perseverance can take a toll on brain health − particularly for people facing social stresses like racism
- Hamas hands over another body in the Gaza Strip
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- This St Nick Truly Can Advise How To Drink And Hack Your Headache
- Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
- Best Wellness Tracker Keep You On target
- Mother and Stepson Rescued After Being Swept Over 6 Miles in Paddleboarding Mishap
- Grasping the Course of Evacuation and Extradition in U.S. Migration
- Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
